Bristol Myers Squibb Stock (BMY): Price, Dividend, Patent Cliff, Pipeline & 2026 Outlook

What Is Bristol Myers Squibb (BMY)?

Bristol Myers Squibb Company (NYSE: BMY) is a global biopharmaceutical company headquartered in New York City. Founded in 1887 and incorporated in its current form following the 1989 merger of Bristol-Myers Company and Squibb Corporation, BMY has grown into one of the world's top 10 pharmaceutical companies by revenue.

BMY focuses on the discovery, development, licensing, manufacturing, and marketing of prescription medicines across four primary therapeutic areas:

• Oncology (Cancer): The largest segment — including Opdivo (nivolumab, checkpoint inhibitor PD-1 antibody), Yervoy (ipilimumab, CTLA-4 inhibitor), Opdualag (combination checkpoint inhibitor), Breyanzi (CAR-T cell therapy), Abecma (CAR-T for multiple myeloma), and Revlimid (immunomodulatory — now facing generic erosion). Reblozyl (luspatercept, hematology/anemia) is a fast-growing newer addition.
• Cardiovascular: Eliquis (apixaban) — co-marketed with Pfizer, Eliquis is one of the world's best-selling drugs and BMY's largest single revenue source as of 2025.
• Immunology / Inflammation: Orencia (abatacept) for rheumatoid arthritis and psoriatic arthritis. Zeposia (ozanimod) for ulcerative colitis and multiple sclerosis.
• Neuroscience: An emerging area for BMY; includes Cobenfy (xanomeline-trospium, schizophrenia — approved 2024, a meaningful new launch).

BMY generated approximately $48.2 billion in full-year 2025 revenue — roughly flat year-over-year — as strong Growth Portfolio gains offset accelerating Legacy Portfolio (Revlimid) erosion. The company has stated its goal of achieving "industry-leading sustainable growth into the 2030s and beyond," backed by a significant pipeline with over 40 clinical assets and ambitious plans to launch up to 10 new medicines by 2030.

For investors tracking BMY's sector context within the broader U.S. healthcare market, InvestSnips covers all 11 GICS sectors and sub-industries across U.S. exchanges, including how pharmaceutical and biotech companies are classified within the healthcare sector.

BMY Financial Snapshot: Revenue, EPS & Key Metrics (2025–2026)

The table below summarizes Bristol Myers Squibb's key financial metrics as of early 2026, based on reported 2025 results and 2026 guidance.

Sources: Bristol Myers Squibb Q4/Full-Year 2025 Earnings Release, Barchart, MarketBeat, Zacks, GuruFocus, Macrotrends. Data as of early 2026. Financial metrics are dynamic — always verify at BMS Investor Relations (bms.com) and SEC EDGAR before making any investment decision.

Legacy vs. Growth Portfolio: The Two-Speed Revenue Story

Bristol Myers Squibb segments its drug portfolio into two buckets — and understanding the gap between them is the most important analytical framework for the BMY investment thesis:

Legacy Portfolio (Declining)

The Legacy Portfolio consists of drugs that have lost or are approaching loss of market exclusivity — primarily Revlimid (lenalidomide), which faced generic entry beginning January 2022, causing a steep multi-year revenue decline. Revlimid was once BMY's largest drug by revenue and has seen dramatic erosion. Pomalyst (pomalidomide) and Sprycel (dasatinib CML) are also classified in the Legacy bucket. The Legacy Portfolio declined approximately 15% in Q4 2025 versus the prior year, and this erosion is expected to continue through 2026–2027.

Growth Portfolio (Expanding)

The Growth Portfolio is BMY's future: newer launches and medications with extended exclusivities and/or first-in-class profiles. Key members as of 2026:

• Opdualag (nivolumab + relatlimab): First-in-class LAG-3 + PD-1 combination for melanoma; growing rapidly due to its clinical differentiation from standard Opdivo monotherapy
• Breyanzi (lisocabtagene maraleucel, liso-cel): CD19-directed CAR-T therapy for lymphoma; growing significantly with expanded indications and improved manufacturing
• Reblozyl (luspatercept): Red blood cell maturation agent approved for anemia in MDS, beta-thalassemia, and myelofibrosis; already approaching "blockbuster" ($1B+ annual) status with further approvals pending (alpha-thalassemia Phase 2 positive data)
• Camzyos (mavacamten): First-in-class cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy (HCM); growing steadily in an underserved disease segment
• Sotyktu (deucravacitinib): First-in-class TYK2 inhibitor for plaque psoriasis; an oral pill differentiated from injectable biologics — targeting a large market
• Cobenfy (xanomeline-trospium, KarXT): Acquired via the Karuna Therapeutics acquisition ($14B, 2024); FDA-approved September 2024 for schizophrenia. First new mechanism in decades. Launch ongoing; considered a potential multi-billion blockbuster
• Opdivo Qvantig (nivolumab subcutaneous): Subcutaneous formulation of Opdivo approved December 2024; key lifecycle extension strategy to extend Opdivo revenue beyond its 2028 IV patent expiration

The Growth Portfolio generated approximately $7.4 billion in Q4 2025 alone, up 15% year-over-year — and its trajectory is accelerating. BMY's financial planning premise for 2026 and beyond is that Growth Portfolio revenue expansion will eventually more than offset Legacy Portfolio declines and Eliquis/Opdivo patent erosion. Whether that transition happens smoothly is the central debate about BMY's long-term investment merit.

The BMY Patent Cliff: Eliquis, Opdivo & What Investors Must Know

The "patent cliff" is the single biggest topic driving both BMY's discounted valuation and its debate among analysts. Here is a precise, updated breakdown:

Eliquis (Apixaban) — The Biggest Drug at Risk

Eliquis is a Factor Xa inhibitor (anticoagulant) co-developed and co-marketed with Pfizer. It is currently BMY's largest revenue-generating drug and one of the top-5 selling drugs globally. Critical timelines:

• European market exclusivity: Expired May 19, 2026 — European generics entered the market in mid-2026, expected to cause a ~15% global Eliquis revenue decline by end of 2026 alone
• U.S. patent protection: Upheld by appeals court; U.S. generics are not expected until approximately April 2028
• BMY's 2026 Eliquis Guidance: Despite European erosion, BMY projects U.S. Eliquis revenue to grow 10–15% in 2026, aided by Medicare strategy (accepting negotiated price to avoid inflation penalty) and direct-to-patient discount programs
• Post-2028 U.S. cliff: When U.S. Eliquis generics launch (~April 2028, though litigation may push this later), this will be the most significant revenue event BMY faces — Eliquis likely generates $10–12+ billion annually; BMY receives roughly 50% of net profits from the Pfizer partnership

Opdivo (Nivolumab) — Lifecycle Extension Strategy

Opdivo is BMY's flagship cancer immunotherapy — a PD-1 checkpoint inhibitor approved across 20+ tumor types and combinations. Timeline:

• Core U.S. PD-1 patents expire approximately 2028
• European exclusivity lost approximately June 2028
• BMY has responded with Opdivo Qvantig — a subcutaneous formulation approved December 2024. Unlike IV Opdivo (30-minute infusion), SubQ Opdivo takes approximately 3–5 minutes. New formulation-specific patents extend exclusivity "well into the 2030s" per BMY management
• BMY also continues expanding Opdivo into new combinations (with Opdualag, with ibrutinib, etc.) and new indications — creating additional patent-protected revenue streams

Revlimid — Already in Decline

Revlimid (lenalidomide) generic erosion began in January 2022. By 2025, Revlimid revenue had declined dramatically from its ~$12B peak towards low single digits. BMY knew this was coming and spent heavily to build the Growth Portfolio accordingly — but the timing overlap of Revlimid decline + Eliquis/Opdivo approaching patent expirations creates a compressed window of pressure. This is why BMY's stock trades at a roughly 40–50% P/E discount to large-cap pharma peers despite its revenue scale.

BMY Pipeline 2026: Iberdomide, Milvexian & Beyond

Bristol Myers Squibb's pipeline is extensive — over 40 clinical compounds across oncology, cardiovascular, immunology, and neuroscience. The two most important near-term catalysts as of 2026:

Iberdomide (CELMoD for Multiple Myeloma) — Priority Review

Iberdomide is an oral cereblon E3 ligase modulator (CELMoD) being developed for relapsed/refractory multiple myeloma — a disease BMY has historically dominated through Revlimid and Pomalyst. Key facts:

• FDA has accepted the NDA (New Drug Application) with Priority Review and Breakthrough Therapy Designation
• PDUFA (target action) date: August 17, 2026
• Iberdomide is designed to be more potent than Revlimid/Pomalyst and to work in patients resistant to those drugs — it directly targets BMY's largest vulnerability (Revlimid erosion) with a next-generation successor
• Peak sales estimates: $3.6 billion+ annually per risk-adjusted analyst models
• Iberdomide is also being studied in combination with mezigdomide (mezigdomide = another CELMoD in mid-stage trials) and standard multiple myeloma backbone therapies

Milvexian (Factor XIa Inhibitor) — Co-developed with J&J

Milvexian is an oral Factor XIa inhibitor being developed jointly by BMY and Johnson & Johnson for multiple cardiovascular indications — and is increasingly viewed as a potential successor drug in the anticoagulation space left by Eliquis's eventual patent erosion:

• Currently in Phase 3 clinical program: Librexia — three concurrent large trials for ischemic stroke, acute coronary syndrome (ACS), and atrial fibrillation
• Factor XIa inhibitors target a different coagulation node than Factor Xa (Eliquis) — potentially with fewer major bleeding events. If Phase 3 data confirms the safety profile advantage, it could become the next-generation anticoagulant
• FDA Fast Track Designation across all three Librexia indications
• Risk-adjusted sales projections (2033): ~$1.2 billion per analyst models (conservative; higher-case estimates go much higher pending Phase 3 data circa 2026–2027)

Other Pipeline Highlights

Pipeline status as of early 2026. Clinical trial timelines are subject to change. Data from BMY investor relations, FDA.gov, and published analyst research. Not investment advice.

For context on how pharmaceutical ETFs and healthcare sector funds capture BMY's pipeline exposure across U.S. equity markets, InvestSnips provides ETF coverage across major U.S. asset classes and sectors, including healthcare-focused index products.

BMY Dividend: Yield, History & Sustainability

For many investors, BMY's most compelling characteristic is its dividend. Here is a complete picture of the current dividend profile:

• Current quarterly dividend: $0.63/share (raised in 2025 — the 17th consecutive year of dividend increases)
• Annual dividend rate: $2.52/share
• Forward dividend yield: ~4.6%+ at prevailing late February 2026 prices (~$62–63/share)
• 5-year dividend CAGR: ~3–6% (sources vary slightly; mid-single-digit range)
• Payout ratio: ~35–40% of adjusted earnings — conservative for a large-cap pharma; leaves meaningful headroom for R&D reinvestment

Dividend Safety Assessment

BMY's dividend is widely considered sustainable through at least 2027, with several supporting factors:

• The 35–40% payout ratio is far below danger thresholds (most analysts flag concern above 70–80% for pharma)
• BMY's 2026 adjusted EPS guidance of $6.05–$6.35 comfortably covers the $2.52 annual dividend (coverage ratio ~2.4–2.5x)
• Free cash flow generation remains robust — BMY's operating cash flow has consistently supported R&D spending, acquisitions, and dividends simultaneously

Dividend Risk Factors

• If Eliquis U.S. generics enter faster than expected (post-April 2028) AND the pipeline disappoints simultaneously, earnings could compress materially — potentially threatening dividend growth (not the current dividend level, but future increases)
• The Karuna ($14B) and SystImmune acquisitions have added to BMY's debt load — servicing that debt is a competing use of cash flow. Total debt is approximately $44–49 billion as of 2025; interest expense is a meaningful drag
• The dividend has not been cut in 17+ years despite periods of extreme pressure (COVID-19, Revlimid generic entry). BMY management has consistently prioritized the dividend as a capital return signal

For income investors tracking dividend payers across the healthcare sector, InvestSnips documents sector-level income characteristics across U.S. equity industries, including pharmaceutical dividend yield comparisons by sub-industry.

BMY Dividend Income Estimator (Interactive)

Use this tool to estimate potential annual and monthly dividend income from a BMY position. Based on BMY's current $2.52/share annual dividend ($0.63/quarter). This is a simplified educational model. Dividend amounts may change. Not a forecast or financial advice.

BMY Valuation: P/E Ratio vs. ABBV, MRK, PFE Peers

Bristol Myers Squibb trades at one of the lowest P/E multiples among large-cap pharmaceutical companies — a discount that reflects patent cliff concerns but may create opportunity if pipeline execution delivers. Compare BMY to its closest large-cap pharma peers:

P/E ratios and yields approximate as of late February 2026. Market caps fluctuate daily. Forward P/E based on consensus 2026E EPS. Sources: GuruFocus, Nasdaq, Morningstar. Not a buy/sell recommendation for any security.

For investors tracking how BMY compares to other high-yield large-cap equities within U.S. market indices, InvestSnips provides data on energy and financial sector compositions within major U.S. equity indexes that can be used alongside pharma sector comparisons for portfolio construction context.

Key Risks of Investing in BMY Stock

1. Patent Cliff — Primary Risk

The pending loss of Eliquis U.S. exclusivity (~April 2028) and Opdivo IV (~2028) represents the largest known headwind BMY faces. Combined, these two drugs likely generate $15–20 billion+ in annual revenue at peak. Even with lifecycle strategies (subcutaneous Opdivo Qvantig, direct-to-patient Eliquis programs), the revenue impact of generic entry will be significant. The degree of this impact and whether the pipeline can compensate is the central unanswered question in the BMY thesis.

2. Acquisition Debt Burden

BMY completed two major acquisitions in 2024: Karuna Therapeutics (~$14B for Cobenfy/KarXT) and SystImmune (~$8.4B for BL-B01D1 ADC in development). Combined with earlier Celgene ($74B, 2019) acquisition debt still on the books, BMY carries a heavy total debt load — approximately $44–49 billion. Interest expense adds $2–3 billion to annual costs, constraining free cash flow allocation. While BMY's earnings cover this comfortably for now, debt levels are a risk amplifier if revenues contract faster than expected.

3. Pipeline Execution Risk

BMY's growth narrative depends heavily on clinical and commercial success of iberdomide, milvexian, Cobenfy's commercial ramp, and Camzyos/Sotyktu/Reblozyl continued expansion. Clinical failures are common in pharmaceuticals. Even late-stage drugs with Priority Review have non-trivial failure rates. Investors should not assume the pipeline will deliver its maximum theoretical value — especially for earlier-stage programs.

4. Medicare Drug Price Negotiation

The Inflation Reduction Act (IRA) allows Medicare to negotiate prices on high-cost drugs. Eliquis was among the first round of drugs subject to negotiation — BMY and Pfizer accepted the negotiated price (reportedly a ~79% discount to list price for Medicare FFS patients) rather than risk inflation penalties. The financial impact is being managed, but future negotiations on other BMY drugs (Opdivo, Revlimid/Pomalyst successors) represent ongoing pricing pressure.

5. Competitive Intensity in Oncology

Opdivo's PD-1 checkpoint inhibitor class now includes Merck's Keytruda (pembrolizumab) — which has gained market share and has more approved indications. Biosimilar versions of PD-1 antibodies are not imminent but will eventually arrive post-patent-expiry. BMY's competitive differentiation in oncology increasingly depends on Opdualag (LAG-3 combination), CAR-T therapies, and next-generation combinations — all requiring continued R&D excellence and label expansion execution.

6. Celgene Integration Complexity

The 2019 $74B Celgene acquisition (which brought Revlimid, Pomalyst, Breyanzi, Reblozyl, and the CELMoD platform) remains the largest pharma deal in history. While mostly integrated, BMY has carried the financial leverage from that deal for years. The long-term ROI of the Celgene acquisition hinges on whether the next-generation CELMoD drugs (iberdomide, mezigdomide) can justify the price paid as Revlimid generics erode.

BMY 2026 Outlook: Catalysts & Headwinds

Near-Term Bullish Catalysts

• Iberdomide FDA Decision (August 17, 2026 PDUFA): A positive approval would validate BMY's CELMoD platform and begin post-Revlimid revenue replacement in the massive multiple myeloma market — this is the single most important binary event for BMY in 2026
• Growth Portfolio momentum: If the Growth Portfolio sustains 15%+ YoY growth into Q1–Q2 2026, it reinforces the revenue replacement thesis and could re-rate BMY's forward multiple upward
• Cobenfy commercial launch ramp: Early prescribing trends and market access data from 2025 will provide first material evidence of Cobenfy's blockbuster potential versus schizophrenia market incumbents
• Cost savings execution: BMY targeting $1B in operational cost reductions for 2026 — if executed, this supports EPS even during top-line transitional pressure
• Milvexian Phase 3 interim data: Any positive data signal from the Librexia trials would dramatically increase BMY's valuation potential in the post-Eliquis era
• 2026 Guidance beats: BMY has built credibility by issuing conservative then beating guidance in recent quarters — continued beats would demonstrate financial narrative control

Near-Term Bearish Risks

• Eliquis European generic entry (May 2026) creating faster-than-expected global revenue erosion
• Iberdomide FDA non-approval or complete response letter (CRL) — would set back BMY's multiple myeloma succession plan by 1–3 years
• Milvexian Phase 3 safety or efficacy miss (bleeding endpoint is critical — Factor XIa inhibitors theoretically bleed less but Phase 3 must prove it)
• Additional Medicare IRA drug price negotiation selections on Opdivo, affecting pricing power estimates
• Macro headwinds: rising rates increasing debt cost; tariff impacts on pharmaceutical supply chains (active pharmaceutical ingredients from China/India)

Frequently Asked Questions About Bristol Myers Squibb Stock (BMY)